Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
Krystal Biotech total assets
Total assets on the balance sheet at the end of each period.
Krystal Biotech's total assets was $1.50B at Jun 30, 2026. For fiscal 2025 it was $1.33B, up 26.3% from the year before. The highest annual figure on record is $1.33B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | +26.3% |
| FY2024 | Dec 31, 2024 | $1.06B | +29.0% |
| FY2023 | Dec 31, 2023 | $818.36M | +46.5% |
| FY2022 | Dec 31, 2022 | $558.45M | -10.8% |
| FY2021 | Dec 31, 2021 | $626.30M | +101.5% |
| FY2020 | Dec 31, 2020 | $310.84M | +48.7% |
| FY2019 | Dec 31, 2019 | $209.02M | +80.0% |
| FY2018 | Dec 31, 2018 | $116.12M | +131.7% |
| FY2017 | Dec 31, 2017 | $50.11M | +2196.7% |
| FY2016 | Dec 31, 2016 | $2.18M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.50B | +31.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.40B | +30.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.33B | +26.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.24B | +26.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.14B | +24.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.07B | +25.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.06B | +29.0% |
| Q3 FY2024 | Sep 30, 2024 | $982.32M | +24.3% |
| Q2 FY2024 | Jun 30, 2024 | $917.66M | +34.2% |
| Q1 FY2024 | Mar 31, 2024 | $853.30M | +60.4% |
| Q4 FY2023 | Dec 31, 2023 | $818.36M | +46.5% |
| Q3 FY2023 | Sep 30, 2023 | $790.35M | +37.1% |
| Q2 FY2023 | Jun 30, 2023 | $684.03M | +13.8% |
| Q1 FY2023 | Mar 31, 2023 | $531.85M | -13.8% |
| Q4 FY2022 | Dec 31, 2022 | $558.45M | -10.8% |
| Q3 FY2022 | Sep 30, 2022 | $576.38M | +27.8% |
| Q2 FY2022 | Jun 30, 2022 | $601.32M | +35.6% |
| Q1 FY2022 | Mar 31, 2022 | $616.87M | +39.2% |
| Q4 FY2021 | Dec 31, 2021 | $626.30M | +101.5% |
| Q3 FY2021 | Sep 30, 2021 | $451.10M | +44.8% |
| Q2 FY2021 | Jun 30, 2021 | $443.56M | +39.4% |
| Q1 FY2021 | Mar 31, 2021 | $443.02M | +116.0% |
| Q4 FY2020 | Dec 31, 2020 | $310.84M | +48.7% |
| Q3 FY2020 | Sep 30, 2020 | $311.45M | +45.4% |
| Q2 FY2020 | Jun 30, 2020 | $318.15M | +55.1% |
| Q1 FY2020 | Mar 31, 2020 | $205.13M | +77.3% |
| Q4 FY2019 | Dec 31, 2019 | $209.02M | +80.0% |
| Q3 FY2019 | Sep 30, 2019 | $214.23M | +293.4% |
| Q2 FY2019 | Jun 30, 2019 | $205.16M | +345.7% |
| Q1 FY2019 | Mar 31, 2019 | $115.70M | +141.8% |
| Q4 FY2018 | Dec 31, 2018 | $116.12M | +131.7% |
| Q3 FY2018 | Sep 30, 2018 | $54.45M | +3.4% |
| Q2 FY2018 | Jun 30, 2018 | $46.03M | +2009.5% |
| Q1 FY2018 | Mar 31, 2018 | $47.85M | – |
| Q4 FY2017 | Dec 31, 2017 | $50.11M | – |
| Q3 FY2017 | Sep 30, 2017 | $52.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.18M | – |
See a number that looks wrong?